Kino T, Stauber R H, Resau J H, Pavlakis G N, Chrousos G P
Pediatric and Reproductive Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892-1583, USA.
J Clin Endocrinol Metab. 2001 Nov;86(11):5600-8. doi: 10.1210/jcem.86.11.8017.
The syndrome of familial or sporadic glucocorticoid resistance is characterized by hypercortisolism without the clinical stigmata of Cushing syndrome. This condition is usually caused by mutations of the human GR, a ligand-activated transcription factor that shuttles between the cytoplasm and the nucleus. A pathological human mutant receptor, in which Ile was replaced by Asn at position 559, had negligible ligand binding, was transcriptionally extremely weak, and exerted a transdominant negative effect on the transactivational activity of the wild-type GR, causing severe glucocorticoid resistance in the heterozygous state. To understand the mechanism of this mutant's trans-dominance, we constructed several N-terminal GR fusion chimeras to green fluorescent protein (GFP) and demonstrated that their transactivational activities were similar to those of the original proteins. The GFP-human (h) GRalphaI559N chimera was predominantly localized in the cytoplasm, and only high doses or prolonged glucocorticoid treatment triggered complete nuclear import that took 180 vs. 12 min for GFP-hGRalpha. Furthermore, hGRalphaI559N inhibited nuclear import of the wild-type GFP-hGRalpha, suggesting that its trans-dominant activity on the wild-type receptor is probably exerted at the process of nuclear translocation. As the ligand-binding domain (LBD) of the GR appears to play an important role in its nucleocytoplasmic shuttling, we also examined two additional GR-related fusion proteins. The natural hGR isoform beta (GFP-hGRbeta), containing a unique LBD, was transactivation-inactive, moderately trans-dominant, and localized instantaneously and predominantly in the nucleus; glucocorticoid addition did not change its localization. Similarly, GFP-hGR514, lacking the entire LBD, was instantaneously and predominantly localized in the nucleus regardless of presence of glucocorticoids. Using a cell fusion system we demonstrated that nuclear export of GFP-hGRalphaI559N (250 min) and GFP-hGRbeta (300 min) was drastically impaired compared with that of GFP-hGRalpha (50 min) and GFP-hGR514 (50 min), suggesting that an altered LBD may impede the exit of the GR from the nucleus. We conclude that the trans-dominant negative effect of the pathological mutant is exerted primarily at the translocation step, whereas that of the natural isoform beta is exerted at the level of transcription.
家族性或散发性糖皮质激素抵抗综合征的特征是皮质醇增多症,但无库欣综合征的临床体征。这种情况通常是由人类糖皮质激素受体(GR)的突变引起的,GR是一种配体激活的转录因子,在细胞质和细胞核之间穿梭。一种病理性人类突变受体,其中第559位的异亮氨酸被天冬酰胺取代,其配体结合能力可忽略不计,转录活性极低,并对野生型GR的反式激活活性产生反式显性负效应,在杂合状态下导致严重的糖皮质激素抵抗。为了了解这种突变体反式显性的机制,我们构建了几种与绿色荧光蛋白(GFP)融合的N端GR嵌合体,并证明它们的反式激活活性与原始蛋白相似。GFP-人(h)GRαI559N嵌合体主要定位于细胞质中,只有高剂量或长时间的糖皮质激素处理才会触发完全的核转运,GFP-hGRα需要12分钟,而GFP-hGRαI559N需要180分钟。此外,hGRαI559N抑制野生型GFP-hGRα的核转运,表明其对野生型受体的反式显性活性可能在核转运过程中发挥作用。由于GR的配体结合结构域(LBD)似乎在其核质穿梭中起重要作用,我们还研究了另外两种与GR相关的融合蛋白。天然的hGR异构体β(GFP-hGRβ)含有独特的LBD,无反式激活活性,具有中等反式显性,瞬时且主要定位于细胞核中;添加糖皮质激素不会改变其定位。同样,缺乏整个LBD的GFP-hGR514无论是否存在糖皮质激素,都瞬时且主要定位于细胞核中。使用细胞融合系统,我们证明与GFP-hGRα(50分钟)和GFP-hGR514(50分钟)相比,GFP-hGRαI559N(250分钟)和GFP-hGRβ(300分钟)的核输出受到严重损害,这表明改变的LBD可能会阻碍GR从细胞核中输出。我们得出结论,病理性突变体的反式显性负效应主要在转运步骤发挥作用,而天然异构体β的反式显性负效应则在转录水平发挥作用。